Supernus Pharmaceuticals
As of the edition of 20 October 2026, Supernus Pharmaceuticals runs 16 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
- Sage Therapeutics: acquired in 2025; successor SUPERNUS PHARMACEUTICALS INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 4 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Topiramate | none listed | 25 |
| Amantadine | none listed | 0 |
| Oxcarbazepine | none listed | 10 |
| Apomorphine | none listed | 1 |
| Brexanolone | none listed | 0 |
| Safinamide | Ends 2028 (patent) | 1 |
| Viloxazine | Ended 2026 (exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| SLC6A2 Sodium-dependent noradrenaline transporter | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Supernus Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 28 trials led
- Nervous system: 21 trials led
- Pregnancy and women's health: 6 trials led